Advance Search

Correlation between Interleukin-1β serum level with severity of airway obstruction in Exacerbation Chronic obstructive pulmonary disease (COPD)

DOI: https://doi.org/10.20956/nmsj.v6i2.18850
Article History

Submited : November 23, 2021
Published : January 16, 2022

Introduction: To observe the relation between Interleukin-1β with exacerbation of Chronic Obstructive Pulmonary Disease (COPD). Methods:  This study was designed for a cross-sectional study. 65 acute exacerbation COPD patients were selected. The serum level of Interleukin-1β was recorded. Results:  Most of the subjects are men (95,4%), moderate smokers (41,5%), normal BMI (61,5%), more than 60 years old (73,8%), have more than 2 exacerbations in a year (67%), severe airway obstruction (41,5%) and mostly in group D (80%). The mean level of Interleukin-1β was 1.63 pg/ml range from 0,009-17,62 pg/ml. Kruskal Wallis analysis test noticed significant differentiation mean serum level of Interleukin-1β in several groups of GOLD. p<0,05. There was no correlation between serum level of IL-1β with the severity of airway obstruction (GOLD) p>0.05. Conclusions: there was no correlation between the severity of airway obstruction with serum level of IL-1β in acute exacerbation of COPD. there was a vicious trend of increasing IL-1β serum level according to the severity of airway obstruction mainly seen in GOLD 2, GOLD 3, and GOLD 4.

References

  1. Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disesease. Glob Initiat Chronic Obstr Lung Disesase. 2020;4.
  2. World health organization. Burden of COPD [Internet]. Available from: https://www.who.int/respiratory/copd/burden/en/
  3. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. The Lancet. 2007;370(9589):765–73.
  4. Wang Y, Xu J, Meng Y, Adcock IM, Yao X. Role of inflammatory cells in airway remodeling in COPD. Int J Chron Obstruct Pulmon Dis. 2018;Volume 13:3341–8.
  5. Ilyas M, Agussalim A, Megawati M, Massi N, Djaharuddin I, Bakri S, et al. Relationship between Vitamin D Level and Serum TNF-α Concentration on the Severity of Chronic Obstructive Pulmonary Disease: Vitamin D Level and Serum TNF-α related to the Severity of Chronic Obstructive Pulmonary Disease. J Med Sci. 2019;7(14):2298–304.
  6. Idris R, Ilyas M, Arief E, Bakri S, Aman AM, Ra H. Profile of Vitamin D and Interleukin-8 in COPD Exacerbation. Clin Med. 2020;07(03):11.
  7. Tanaka T, Narazaki M, Kishimoto T. IL-6 in Inflammation, Immunity, and Disease. Cold Spring Harb Perspect Biol. 2014;6(10):a016295–a016295.
  8. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, et al. Azithromycin for Prevention of Exacerbations of COPD. N Engl J Med. 2011;365(8):689–98.
  9. Lopez-Castejon G, Brough D. Understanding the mechanism of IL-1β secretion. Cytokine Growth Factor Rev. 2011;22(4):189–95.
  10. Osei ET, Brandsma C-A, Timens W, Heijink IH, Hackett T-L. Current perspectives on the role of interleukin-1 signalling in the pathogenesis of asthma and COPD. Eur Respir J. 2020;55(2):1900563.
  11. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183–92.
  12. Muzarti D. Correlation between Anxiety and Depression with Quality of Life among Chronic Obstructive Pulmonary Disease Patients. J Respir Indo. 2019;39(2):121–9.
  13. Tsai T-Y, Livneh H, Lu M-C, Tsai P-Y, Chen P-C, Sung F-C. Increased risk and related factors of depression among patients with COPD: a population-based cohort study. BMC Public Health. 2013;13(1):976
  14. Kwon H, Kim E. Factors contributing to quality of life in COPD patients in South Korea. Int J Chron Obstruct Pulmon Dis. 2016;103.
  15. Oemiati R. Kajian Epidemiologis Penyakit Paru Obstruktif Kronik (PPOK). 23(2):7.
  16. Department of Economic and Social Affairs Population Division. World population ageing 2013. New York: United Nation; 2013. 3 p.
  17. Raherison C, Girodet P-O. Epidemiology of COPD. Eur Respir Rev. 2009;18(114):213–21.
  18. Sng J, Thomas P. COPD: Immunopathogenesis and Immunological Markers. Adv Res. 2015;3(2):221–35.
  19. Donaldson GC. COPD exacerbations : Epidemiology. Thorax. 2006;61(2):164–8.
  20. Silva BSA, Lira FS, Ramos D, Uzeloto JS, Rossi FE, Freire APCF, et al. Severity of COPD and its relationship with IL-10. Cytokine. 2018;106:95–100.
  21. Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, et al. Pneumonia Risk with Inhaled Fluticasone Furoate and Vilanterol Compared with Vilanterol Alone in Patients with COPD. Ann Am Thorac Soc. 2015;12(1):27–34.
  22. Garcia-Aymerich J, Gomez FP, Benet M, Farrero E, Basagana X, Gayete A, et al. Identification and prospective validation of clinically relevant chronic obstructive pulmonary disease (COPD) subtypes. Thorax. 2011;66(5):430–7.
  23. Hurst JR, Locantore N, Miller B, MacNee W, Rennard S, Wedzicha JA. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2010;11.
  24. Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–63.
  25. Rosenwasser LJ. Biologic activities of IL-1 and its role in human disease. Essayan DM, Fox CC, Levi-Schaffer F, Alam R, editors. J Allergy Clin Immunol. 1998;102(3):344–50.
  26. Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. Interleukin-1β Causes Pulmonary Inflammation, Emphysema, and Airway Remodeling in the Adult Murine Lung. Am J Respir Cell Mol Biol. 2005;32(4):311–8.
  27. Mahajan B, Vijayan VK, Agarwal MK, Bansal SK. Serum interleukin-1β as a marker for differentiation of asthma and chronic obstructive pulmonary disease. Biomarkers. 2008;13(7–8):713–27.
  28. Singh B, Arora S, Khanna V. Association of severity of COPD with IgE and interleukin-1beta. Monaldi Arch Chest Dis [Internet]. 2016 Jan 19;73(2).
  29. Amer M, Wahba HodaMF, Ashmawi SamihaSA, Mabrouk R, Sharaf AhmadAE, Hamza S. Proinflammatory cytokines in Egyptian elderly with chronic obstructive pulmonary disease. Lung India. 2010;27(4):225.
  30. Sapey E, Ahmad A, Bayley D, Newbold P, Snell N, Rugman P, et al. Imbalances Between Interleukin-1 and Tumor Necrosis Factor Agonists and Antagonists in Stable COPD. J Clin Immunol.
  31. Oudijk E-JD. Systemic inflammation in COPD visualised by gene profiling in peripheral blood neutrophils. Thorax. 2005;60(7):538–44.
  32. Zou Y, Chen X, Liu J, Zhou D bo, Kuang X, Xiao J, et al. Serum IL-1β and IL-17 levels in patients with COPD: associations with clinical parameters. Int J Chron Obstruct Pulmon Dis. 2017;Volume 12:1247–54.
  33. Hammad DR, Elgazzar AG, Essawy TS, Sameie S. Evaluation of serum Interleukin-1 beta as an inflammatory marker in COPD patients. Egyptian Journal of Chest Disease and Tuberculosis;2015:64.347-352.
Budi Mulya, N., Ilyas, M., Arief, E. ., Djaharuddin, I., Nurisyah, S., & Putrawan, H. A. . (2022). Correlation between Interleukin-1β serum level with severity of airway obstruction in Exacerbation Chronic obstructive pulmonary disease (COPD). Nusantara Medical Science Journal, 6(2), 93-102. https://doi.org/10.20956/nmsj.v6i2.18850

Copyright (c) 2021 Array

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Downloads

Download data is not yet available.
Fulltext
PDF